NeuroVive Stock Now Trading in the USA on the OTC Market
ET | Source:NeuroVive Pharmaceutical AB
NeuroVive Pharmaceutical AB stock shares were registered with the OTC Reporting
Facility for Foreign shares in New York City with the ticker symbol NEVPF:US on
March 20, 2014. NeuroVive trades on the NASDAQ OMX Stockholm (Sweden) Small Cap
since April 2013 with ticker symbol NVP.ST. The NEVPF shares have been trading
in the United States between $4.00 and $4.21, reflecting the Swedish market
NeuroVive Pharmaceutical AB’s inclusion in the Grey Market OTC trading means the
share now trades electronically on the US market through domestic American full
-service and internet brokerages houses. The NEVPF ticker symbol registration
was placed by an American retail brokerage firm.
This extends the NeuroVive stock trading day from the Nordic countries to North
America, and by five and half hours until US market closing at 5 p.m. EST (11
p.m. Swedish or Central European Time). OTC trading makes it straightforward for
US investors to easily and electronically invest in NeuroVive using US currency,
with no need to go through a Swedish brokerage nor convert Swedish krona (SEK).
NEVPF share price can be followed at www.OTCmarkets.com, or through any American
This early registration of NeuroVive on the American market occurred because
over 4 million NeuroVive shares, or over 15% of all NeuroVive shares are already
in American brokerage houses. The majority of NEVPF shares are held at E*Trade
Securities LLC by Maas Biolab, LLC, the American company that is the largest
shareholder of NeuroVive. Individuals also hold NEVPF shares in other American
brokerages and branches including Charles Schwab, Fidelity, Janney Montgomery
Scott, Morgan Stanley and UBS.
OTC Markets Group's Open, Transparent and Connected financial marketplaces
provide investors with the information necessary to intelligently analyze, value
and trade 10,000 U.S. and global securities through the broker of their choice.
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(heart attack) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of anti-viral indications
(Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for
cellular protection and treating mitochondria-related energy regulation
diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.
For media and investor relations questions, please contact:
Ingmar Rentzhog, Laika Consulting, tel: +46 (0)46 275 62 21 or firstname.lastname@example.org
It is also possible to arrange an interview with NeuroVive’s CEO Mikael
Brönnegård via the contact above.
NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: + 46 (0)46 888 83 48,
NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on 10 April 2014, at 8:30 a.m. CET.
other press releases byNeuroVive Pharmaceutical AB
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.